U.S. markets open in 1 hour 2 minutes
  • S&P Futures

    3,820.50
    -13.50 (-0.35%)
     
  • Dow Futures

    30,855.00
    -81.00 (-0.26%)
     
  • Nasdaq Futures

    11,753.50
    -55.00 (-0.47%)
     
  • Russell 2000 Futures

    1,732.10
    -9.60 (-0.55%)
     
  • Crude Oil

    100.44
    +0.94 (+0.94%)
     
  • Gold

    1,762.70
    -1.20 (-0.07%)
     
  • Silver

    19.23
    +0.11 (+0.57%)
     
  • EUR/USD

    1.0171
    -0.0099 (-0.97%)
     
  • 10-Yr Bond

    2.8090
    0.0000 (0.00%)
     
  • Vix

    28.02
    +0.49 (+1.78%)
     
  • GBP/USD

    1.1877
    -0.0075 (-0.63%)
     
  • USD/JPY

    135.1000
    -0.7420 (-0.55%)
     
  • BTC-USD

    20,128.73
    +637.43 (+3.27%)
     
  • CMC Crypto 200

    436.08
    -3.95 (-0.90%)
     
  • FTSE 100

    7,133.98
    +108.51 (+1.54%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

BlueAllele® Corporation continues to advance therapeutic approaches using novel gene correction technologies and secures third patent from the USPTO

·3 min read

OAKDALE, Minn., June 21, 2022 /PRNewswire/ -- BlueAllele® Corporation, a biotechnology company focused on advancing transformational gene correction technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,365,407 (the '407 Patent) related to its proprietary in vivo gene correction methodologies.

BlueAllele logo (PRNewsfoto/BlueAllele)
BlueAllele logo (PRNewsfoto/BlueAllele)

BlueAllele was founded with the ambitious objective to develop methodologies for single-dose treatments to cure the most debilitating and devastating genetic diseases. Over 5,000 genetic diseases, which are caused by mutations within a gene, have been identified and diagnosed in humans. The mutations can inactivate gene function, referred to as loss-of-function mutations, or create an undesirable function, referred to as gain-of-function mutations. BlueAllele has developed transformational gene correction technologies utilizing its proprietary PALIDON® repair template platforms to achieve gene correction that is precise, durable, and capable of treating a broad range of both loss-of-function and gain-of-function mutations.

Dr. Nicholas Baltes, BlueAllele's chief scientific officer, said, "We saw that there was a large gap in the capabilities of the genetic tools for gene correction and the development of effective, safe and lifelong therapies. We set out to close the gap."

Unlike traditional gene therapy where the corrective sequences remain extrachromosomal, PALIDON is integrated into the cell's DNA thereby providing potential lifelong therapeutic effects. Further, unlike gene knockout approaches where gene function is destroyed, PALIDON provides replacement sequence for restoration of gene function.

The distinctive palindromic design of BlueAllele's PALIDON repair templates has unlocked the full potential of the cell's highly active NHEJ pathway. In doing so, PALIDON can increase the efficacy of gene correction events, improve safety and be used for the therapeutic treatment of a wide range of diseases. BlueAllele has expanded upon this foundational feature with the design of additional repair template platforms for treating specific classes of genetic diseases. PALIDON+™ was designed for autosomal dominant diseases and functions to remove unwanted gene products while simultaneously restoring normal protein function. PALIDON DT™ was designed to address repeat expansion diseases and functions to prevent transcription through the expansion.

"We are excited about the potential of our PALIDON platforms for gene correction in patients," said Joseph B. Saluri, BlueAllele's chief executive officer. "What was once considered beyond reach is now closer to becoming a reality."

About BlueAllele's Patents

The newly granted '407 Patent includes claims covering adeno-associated viral vectors harboring BlueAllele's proprietary PALIDON transgene design. The claims also cover adeno-associated viral vectors harboring a PALIDON transgene containing Factor 9 coding sequences for treating patients with hemophilia B.

U.S. Patent 11,254,930 (the '930 Patent) includes claims covering recombinant nucleic acids containing BlueAllele's novel PALIDON transgene structure, which includes splice acceptors, coding sequences and terminators for correcting gene function. The PALIDON transgenes can be used with any nuclease, any delivery system and any application for treating a genetic disease in any tissue or cell.

U.S. patent 11,091,756 (the '756 Patent) includes claims covering methods for using PALIDON to edit genes in any cell type and system, in vitro or in vivo applications, as well as its use for correcting any gene in the genome.

The '407, '930 and '756 Patents are exclusively owned by BlueAllele Corporation and provide broad coverage for the development and advancement of human gene correction technologies.

BlueAllele Corporation is a biotechnology company committed to advancing transformational gene correction technologies, including its patented PALIDON® PALIDON+™ and PALIDON DT™ repair template platforms. BlueAllele is a member of Medical Alley, The Global Epicenter of Health Innovation and Care™. For more information, visit www.blueallele.com.

BlueAllele is seeking strategic collaborators for leading innovation for gene correction technologies. If interested, please contact us via www.blueallele.com/contact.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueallele-corporation-continues-to-advance-therapeutic-approaches-using-novel-gene-correction-technologies-and-secures-third-patent-from-the-uspto-301572324.html

SOURCE BlueAllele